The Wall Street Journal on Wednesday examined how “pediatric experts are wrestling with an emotionally fraught issue: whether to let some babies at risk for a potentially serious respiratory virus take their chances with the disease or to preventively administer an expensive drug that may or may not work.” Palivizumab, a synthetic antibody marketed by